All News about Frequency Therapeutics, Inc. - Common Stock
![](https://cdn.benzinga.com/files/images/story/2022/07/08/image40.jpg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220518005346/en/747672/5/Frequency-Logo.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_8004.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_6187.jpeg)
![](https://mms.businesswire.com/media/20220504005229/en/747672/5/Frequency-Logo.jpg)
![](https://mms.businesswire.com/media/20220422005075/en/1428939/5/Frequency-Logo.jpg)
![](https://investorplace.com/wp-content/uploads/2021/05/wall-street-morning.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/04/19/yesterdays_movers.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_6731.jpeg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_4112.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20220228005115/en/1372264/5/Frequency-Logo.jpg)
![](https://mms.businesswire.com/media/20220104005237/en/1317233/5/Frequency-Logo.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_404.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_2803.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3550.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3443.jpeg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_3336.jpeg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2022/movers_image_2271.jpeg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/movers_image_4081.jpeg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_98.jpg)
NASDAQ:FREQ Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Frequency Therapeutics, Inc.
September 29, 2021
Via SBWire
Topics
Lawsuit
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_94.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1940.png)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.